Brown Advisory Inc. Buys 1,062,887 Shares of LifeStance Health Group, Inc. (NASDAQ:LFST)

Brown Advisory Inc. increased its position in shares of LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) by 25.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,158,980 shares of the company's stock after buying an additional 1,062,887 shares during the period. Brown Advisory Inc. owned 1.36% of LifeStance Health Group worth $40,395,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in LFST. Principal Financial Group Inc. raised its holdings in shares of LifeStance Health Group by 4.5% in the 3rd quarter. Principal Financial Group Inc. now owns 3,895,887 shares of the company's stock valued at $26,765,000 after purchasing an additional 168,091 shares during the period. Jump Financial LLC acquired a new stake in shares of LifeStance Health Group in the third quarter valued at approximately $157,000. Barclays PLC boosted its stake in shares of LifeStance Health Group by 37.1% during the 3rd quarter. Barclays PLC now owns 47,561 shares of the company's stock worth $327,000 after acquiring an additional 12,858 shares during the period. Keybank National Association OH increased its holdings in shares of LifeStance Health Group by 37.9% during the 3rd quarter. Keybank National Association OH now owns 26,587 shares of the company's stock worth $183,000 after acquiring an additional 7,303 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of LifeStance Health Group by 1.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 739,505 shares of the company's stock worth $5,080,000 after acquiring an additional 7,868 shares during the last quarter. 85.50% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

LFST has been the subject of a number of research analyst reports. The Goldman Sachs Group lifted their price objective on shares of LifeStance Health Group from $8.00 to $9.00 and gave the stock a "neutral" rating in a research report on Monday, March 4th. Barclays lifted their target price on shares of LifeStance Health Group from $7.00 to $8.00 and gave the stock an "underweight" rating in a report on Thursday, February 29th. Morgan Stanley reissued an "overweight" rating and issued a $10.00 price target on shares of LifeStance Health Group in a report on Monday, April 22nd. Finally, Jefferies Financial Group boosted their price objective on LifeStance Health Group from $8.00 to $9.00 and gave the stock a "buy" rating in a report on Wednesday, March 6th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $8.80.

LifeStance Health Group Stock Performance

Shares of LFST stock traded up $0.02 on Friday, hitting $7.39. The company's stock had a trading volume of 645,928 shares, compared to its average volume of 1,131,638. LifeStance Health Group, Inc. has a fifty-two week low of $4.74 and a fifty-two week high of $9.59. The company has a market capitalization of $2.83 billion, a PE ratio of -15.40 and a beta of 1.29. The stock's 50 day moving average is $6.37 and its 200-day moving average is $6.65. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.18 and a current ratio of 1.18.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.09) by $0.03. LifeStance Health Group had a negative return on equity of 11.92% and a negative net margin of 15.69%. The company had revenue of $300.44 million for the quarter, compared to analysts' expectations of $299.02 million. During the same quarter last year, the business earned ($0.09) earnings per share. LifeStance Health Group's revenue was up 18.9% on a year-over-year basis. Equities research analysts expect that LifeStance Health Group, Inc. will post -0.27 earnings per share for the current fiscal year.

Insider Transactions at LifeStance Health Group

In related news, insider Danish J. Qureshi sold 12,965 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $5.93, for a total transaction of $76,882.45. Following the sale, the insider now owns 4,911,050 shares in the company, valued at approximately $29,122,526.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Kevin Michael Mullins sold 115,136 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $8.02, for a total value of $923,390.72. Following the completion of the transaction, the insider now owns 4,575,480 shares of the company's stock, valued at $36,695,349.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Danish J. Qureshi sold 12,965 shares of the firm's stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $5.93, for a total transaction of $76,882.45. Following the completion of the sale, the insider now owns 4,911,050 shares in the company, valued at $29,122,526.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 295,741 shares of company stock valued at $2,149,435. Company insiders own 6.60% of the company's stock.

LifeStance Health Group Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.